CRYSTALLINE FORMS OF AN ANTIDEPRESSANT COMPOUND
    7.
    发明申请
    CRYSTALLINE FORMS OF AN ANTIDEPRESSANT COMPOUND 有权
    抗菌化合物的结晶形式

    公开(公告)号:US20160015706A1

    公开(公告)日:2016-01-21

    申请号:US14791736

    申请日:2015-07-06

    IPC分类号: A61K31/495

    CPC分类号: A61K31/495 C07D295/096

    摘要: The present invention relates to novel crystalline forms of vortioxetine hydrobromide, in particular three crystalline forms, a process for their preparation, a pharmaceutical composition containing said novel crystalline forms, and a process for the purification of vortioxetine or a salt thereof, comprising the formation of one or more of the novel crystalline forms of vortioxetine hydrobromide described herein.

    摘要翻译: 本发明涉及新型的伏坦托龙氢溴酸盐的结晶形式,特别是三种结晶形式,其制备方法,含有所述新结晶形式的药物组合物,以及用于纯化维生素A或其盐的方法,包括形成 本文所述的一种或多种本文中的一种或多种本文形式的伏立酮氢溴酸盐。

    CRYSTALLINE FORMS OF AN ADRENERGIC AGONIST
    8.
    发明申请
    CRYSTALLINE FORMS OF AN ADRENERGIC AGONIST 审中-公开
    ADRENERGIC AGONIST的晶体形式

    公开(公告)号:US20150111934A1

    公开(公告)日:2015-04-23

    申请号:US14505528

    申请日:2014-10-03

    IPC分类号: C07D277/40

    CPC分类号: C07D277/40

    摘要: The present invention relates to the acetate salt of Mirabegron, in particular in two novel crystalline forms, a process for their preparation and the use of said salt and its crystalline forms in the synthesis of Mirabegron with high yields and chemical purity.

    摘要翻译: 本发明涉及Mirabegron的乙酸盐,特别是两种新的结晶形式,它们的制备方法以及所述盐及其结晶形式在Mirabegron合成中的高产率和化学纯度的用途。